Consequently, the ATR/CHK1 pathway represents a vulnerability for tumors in which latent RS can be awakened [105] and, consistently, MYC-driven cancers are highly sensitive to ATR and CHK1 inhibitors as single agents [106,107,108,109]. Here, MYC is linked to cancer.